Dilated Pulmonary Artery in Marfan syndrome

Dilated Pulmonary Artery in Marfan syndrome

Overview

Marfan syndrome is an autosomal dominant connective tissue disorder caused by mutations in the FBN1 gene, leading to abnormal fibrillin-1 and weakness of elastic tissues. Cardiovascular involvement classically affects the aorta, but dilation of the pulmonary artery (PA) is a recognized, though under-discussed, manifestation. Pulmonary artery dilation in Marfan syndrome reflects the same underlying medial degeneration that affects the aorta and can have diagnostic and prognostic significance.

Pathophysiology

The pulmonary artery wall, like the aorta, is rich in elastic fibers. In Marfan syndrome, defective fibrillin-1 results in:

• Fragmentation of elastic fibers

• Medial degeneration and cystic medial necrosis

• Reduced tensile strength of the vessel wall

Although pulmonary artery pressures are normally much lower than systemic pressures, chronic exposure to abnormal wall stress can still lead to progressive dilation. This explains why PA dilation can occur even in the absence of pulmonary hypertension.

Prevalence and Clinical Context

Pulmonary artery dilation is less common and less severe than aortic dilation in Marfan syndrome. It is most often detected incidentally during echocardiography or CT/MR imaging performed for aortic assessment. Key points include:

• More frequent in adults than children

• Often associated with concomitant aortic root dilation

• Usually asymptomatic

In contrast to other causes of PA dilation, such as pulmonary hypertension or congenital shunts, Marfan-related PA dilation often occurs with normal pulmonary artery pressures.

Imaging Findings

Echocardiography

• Dilated main pulmonary artery diameter

• Normal or mildly increased right-sided pressures

• Often seen alongside a dilated aortic root

CT and Cardiac MRI

• Accurate measurement of main and branch pulmonary arteries

• Smooth, fusiform dilation rather than focal aneurysm

• Absence of mural thrombus or dissection in most cases

There is no universally accepted cutoff for abnormal PA size in Marfan syndrome, but a main PA diameter >29 mm in adults is generally considered enlarged, with indexing to body surface area improving accuracy.

Clinical Significance

In most patients, pulmonary artery dilation is benign and does not lead to complications. However, its presence is important because:

• It reflects the systemic nature of connective tissue weakness

• It supports the diagnosis in borderline or atypical cases

• Rarely, massive dilation can predispose to PA aneurysm or rupture

Importantly, PA dilation in Marfan syndrome should not automatically be attributed to pulmonary hypertension without hemodynamic confirmation.

Differential Diagnosis

When a dilated pulmonary artery is identified in a Marfan patient, alternative or additional causes should be excluded:

• Pulmonary hypertension

• Left-to-right shunts (ASD, PDA)

• Chronic thromboembolic disease

• Other connective tissue disorders

Normal right heart pressures and absence of shunts favor Marfan-related structural dilation.

Management and Follow-Up

There are no specific guideline-directed therapies for isolated pulmonary artery dilation in Marfan syndrome. Management principles include:

• Regular imaging surveillance when significant dilation is present

• Optimization of overall Marfan cardiovascular care (beta-blockers or ARBs as indicated for aortic disease)

• Avoidance of unnecessary intervention unless complications develop

Surgical or endovascular treatment is rarely required and reserved for extreme dilation, rapid progression, or complications.

Key Takeaway

Dilated pulmonary artery in Marfan syndrome is a manifestation of generalized connective tissue weakness rather than elevated pulmonary pressures. It is usually incidental, clinically silent, and best managed with awareness, appropriate imaging follow-up, and exclusion of secondary causes.